By continuing to use our site, you agree to our use of cookies, our Terms & Conditions and Privacy Policy.
Uterine Leiomyosarcoma nomogram: 5 year overall survivall
Current model is an externally validated nomogram predicting the five-year overall survival in patients with Uterine Leiomyosarcoma. 

Note: This model calculates the nomogram published in the original article (see files & references) and may be deviant from the MSKCC web-calculator as the full cox-regression formula is not provided. 
Research authors: Oliver Zivanovic, Lindsay M. Jacks, Alexia Iasonos, Mario M. Leitao, Jr. , Robert A. Soslow, Emanuela Veras, Dennis S. Chi, Nadeem R. Abu-Rustum, Richard R. Barakat, Murray F. Brennan, Martee L. Hensley
Details Formula Study characteristics Files & References
★★★★
Model author
T. A. Hueting
Model ID
1098
Version
1.12
Revision date
2018-01-22
Specialty
Gynaecology, Oncology
MeSH terms
  • Gynecology
  • Leiomyosarcoma
  • Cancer Staging
    • Model type
    Custom model (Conditional)
    Status
    public
    Rating
    ★ ★ ★ ★
    Share
    Condition Formula

    Additional information

    During the study period, 270 patients presented with pathologically confirmed uterine leiomyosarcoma. Patients with 1 or more missing nomogram values (n = 85) were excluded, leaving 185 patients for the nomogram analysis. There were no significant differences between the whole cohort (n = 270) and the nomogram cohort (n = 185) with regard to follow-up, median OS, and clinical characteristics. There was no statistically significant difference in OS between patients who received no further treatment versus those who received any type of postresection treatment. In addition, there was no statistically significant difference in stage-specific OS (by either FIGO or AJCC) between patients who received no further treatment versus those who received any type of postresection treatment.

    Study Population

    Total population size: 185

    Continuous characteristics

    Name LL Q1 Median Q3 UL Unit
    Age 23 51 81 years
    Tumor size 0.9 9 28 cm
    Mitotic index 1 15 200 mitosis/HPF
    Survival (follow-up) 0.33 5.4 22.83 year

    Categorical characteristics

    Name Subset / Group Nr. of patients
    High tumor grade No 16
    Yes 169
    Locoregional metastases Yes 52
    No 133
    Distant metastases Yes 34
    No 151
    Postresection treatment Chemotherapy 43
    Chemoradiation therapy 7
    Radiation therapy 14
    No treatment 73
    Not specified 48
    FIGO stage I 107
    II 14
    III 31
    IV 33
    Follow-up No. of survivors 74
    Patient status Alive without disease 44
    Alive with disease 30
    Dead of disease 106
    Dead, not disease related 1
    Dead of unknown state 4

    Related files

    Supporting Publications

    The 5-year overall survival probability is:
    ...     %

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    The 5-year overall survival probability is: %

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    Results from the external validation study showed that the nomogram concordance index was 0.67(SE=0.02), which was as high as the concordance index from the initial cohort used for nomogram development. The concordance between actual overall survival and nomogram predictions suggests excellent calibration since predictions were within 1% of actual 5-year overall survival rates for patients with a predicted 5-year OS of less than 0.68.
     

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    Recent Oncology Models
    Preoperative risk of positive surgical margins in breast-conserving surgery
    EORTC risk tables: Predicting recurrence and progression in stage Ta T1 bladder cancer patients.
    Predicting Extrapelvic Disease following primary radiation therapy for prostate cancer
    Partin tables update 2016 by Tosoian et al.
    EORTC risk tables: Predicting recurrence and progression in stage Ta T1 bladder cancer patients. (1yr Recurrence)
    All Oncology Models
    Recent Gynaecology Models
    Preoperative risk of positive surgical margins in breast-conserving surgery
    ADNEX model: Benign tumor
    fullPIERS: Pre-eclampsia Integrated Estimate of RiSk (recalibrated)
    fullPIERS: Pre-eclampsia Integrated Estimate of RiSk
    PREP models: Prediction of complications in early-onset pre-eclampsia
    All Gynaecology Models
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}

    Evidencio Community Account Benefits

    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.
    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
    Evidencio v2.16 © 2015 - 2020 Evidencio. All Rights Reserved | Terms & Conditions | Privacy Policy | Disclaimer | Contact